Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, Iurlo A, Kim I, Rose S, Brown P, Hernandez C, Wang J, Kiladjian JJ. Harrison CN, et al. Among authors: passamonti f. Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9. Lancet Haematol. 2024. PMID: 39265613 Clinical Trial.
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET; Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG; GenoMed4all and Synthema Consortiums. Tentori CA, et al. J Clin Oncol. 2024 Aug 20;42(24):2873-2886. doi: 10.1200/JCO.23.02175. Epub 2024 May 9. J Clin Oncol. 2024. PMID: 38723212 Free PMC article.
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
Tiacci E, Mancini A, Marchetti M, D'Elia GM, Candoni A, Morotti A, Romano A, Gozzetti A, Broccoli A, De Carolis L, Bruna R, Tisi MC, Selleri C, Capponi M, Vallisa D, Cattaneo C, Della Porta MG, Busca A, Falini B, Massaia M, Bertù L, Pulsoni A, Rivela P, Corradini P, Passamonti F. Tiacci E, et al. Among authors: passamonti f. Br J Haematol. 2023 May;201(3):411-416. doi: 10.1111/bjh.18606. Epub 2022 Dec 20. Br J Haematol. 2023. PMID: 36541031 Free PMC article.
Using real-world evidence in haematology.
Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Della Porta MG, Gale RP. Passamonti F, et al. Best Pract Res Clin Haematol. 2024 Mar;37(1):101536. doi: 10.1016/j.beha.2024.101536. Epub 2024 Jan 27. Best Pract Res Clin Haematol. 2024. PMID: 38490764 Review.
Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept.
Fattizzo B, Marchetti A, Zaninoni A, Lionetti M, Riva M, Rizzo L, Pettine L, Galli N, Mazzon F, Fermo E, Maeda A, Marella A, Da Vià MC, Passamonti F, Bolli N, Barcellini W. Fattizzo B, et al. Among authors: passamonti f. Am J Hematol. 2023 Nov;98(11):E345-E348. doi: 10.1002/ajh.27072. Epub 2023 Sep 12. Am J Hematol. 2023. PMID: 37698348 Free article. No abstract available.
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
Harrison CN, Mesa R, Talpaz M, Gupta V, Gerds AT, Perkins A, Goh YT, Fox ML, McLornan D, Palmer J, Foltz L, Vannucchi A, Koschmieder S, Passamonti F, Lee SE, Ellis C, Strouse B, Gonzalez Carreras FJ, Oh ST. Harrison CN, et al. Among authors: passamonti f. Clin Lymphoma Myeloma Leuk. 2024 Oct 16:S2152-2650(24)02359-0. doi: 10.1016/j.clml.2024.10.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39516087 Free article.
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.
Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri PP, Summa V, Guarcello A, Palumbo GA, Pane F, Guglielmelli P, Corradini P, Russo P. Breccia M, et al. Among authors: passamonti f. Br J Haematol. 2024 Oct 3. doi: 10.1111/bjh.19812. Online ahead of print. Br J Haematol. 2024. PMID: 39363576
Natural history of chronic idiopathic neutropenia of the adult.
Fattizzo B, Bosi A, Sorrenti M, Murgia D, Pettine L, Bortolotti M, Croci GA, Passamonti F, Barcellini W. Fattizzo B, et al. Among authors: passamonti f. Sci Rep. 2024 Sep 19;14(1):21891. doi: 10.1038/s41598-024-71719-2. Sci Rep. 2024. PMID: 39300133 Free PMC article.
433 results